The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018

• Autores: Kjell Öberg
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 47, Nº. 3, 2018 (Ejemplar dedicado a: Innovations in the Management of Neuroendocrine Tumors), págs. 711-731
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The concept of neuroendocrine tumors (NETs) began in the 1900s with Oberndorfer’s description of carcinoid tumors, followed by specific cytotoxic agents and the identification of somatostatin. NETs diagnosis was confirmed by World Health Organization classification. Histopathology included immunohistochemistry with specific antibodies. Imaging was refined with molecular imaging. Somatostatin is the leading agent for controlling clinical symptoms related to hormone production. Increasing interest in these tumors, previously thought rare, led to increased incidence and prevalence. Between 1960 and 1970, the true NET-concept was established with development of radioimmunoassays for peptides and hormones, and imaging with computerized tomography.